Genetron Holdings Limited (NASDAQ: GTH)
|
|
---|---|
Pricing data not available |
Open: | $ n/a | Volume: | n/a | |
---|---|---|---|---|
High: | $ n/a | Yield(%) | n/a | |
Low: | $ n/a | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | n/a | |
EPS ($) | n/a | Shares Out: | n/a |
% Price Change (last 4 weeks): | 0.00 |
---|---|
% Price Change (last 13 weeks): | 0.00 |
% Price Change (last 26 weeks): | 9.08 |
% Price Change (last 52 weeks): | 41.21 |
% Price Change (year to date): | 9.51 |
Return on Equity (%): | -89.69 |
---|---|
Return on Assets (%): | -63.45 |
Return on Invested Capital (%): | -154.79 |
Gross Profit Margin (%): | 43.25 |
---|---|
Net Profit Margin (%): | -124.23 |
Operating Profit Margin (%): | -107.47 |
|
|
50-day Moving Average: | $n/a |
---|---|
200-day Moving Average: | $n/a |
Avg. Daily Vol. (last 50 days): | n/a |
Avg. Daily Vol. (last 200 days): | n/a |
52-wk high: | $n/a |
52-wk low: | $n/a |
Bid: | $n/a |
Ask: | $n/a |
Genetron Holdings, Ltd. engages in precision oncology. It provides cancer molecular profiling by using technologies in molecular biology and data science to transform cancer treatment. It products and services include diagnosis and monitoring through both LDT and IVD products. Its LDT portfolio consists of both specifically designed focused and comprehensive gene panel testing services. It also develops liver cancer early screening products. The company was founded by Si Zhen Wang, Hai Yan, and Wei Wu He in 2015 and is headquartered in Beijing, China.
|
Genetron Holdings Limited
1-2F Building 11, Zone 1 8 Life Science Parkway Changping District Beijing BE 102206 Phone: 86.10.5090.7500 Fax: n/a http://ir.genetronhealth.com |
Earnings (1year) ($): | -3.54 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 2.58 |
Cash Flow ($): | -3.56 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 1.08 |
Price/Book (x): | 1.30 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 1.71 |
---|---|
Current Ratio (x): | 1.82 |
LT Debt/Equity (x): | 5.01 |
Total Debt/Equity (x): | 29.04 |